Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Leukaemia drug fast-tracked by NICE

January 6, 2011
Sales and Marketing Bendamustine, Levact, NICE, Napp, chronic lymphocytic leukaemia, leukaemia

A treatment for patients with the most common form of leukaemia has been fast tracked by NICE because of strong …

News

NICE’s public health role reduced

January 4, 2011
NHS, NHS reforms, NICE, public health, quality standards

NICE’s public health remit has been slimmed down as part of the government’s reforms with the removal of six areas …

News

GSK’s patient access scheme for Votrient sways NICE

December 24, 2010
Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …

News
Avastin packs

NICE no for Avastin in breast cancer

December 8, 2010
Sales and Marketing NICE, Roche, avastin, bevacizumab, breast cancer, health technology assessment, hta

NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …

News
Roche's MabThera

NICE recommends MabThera for non-Hodgkin’s lymphoma

December 6, 2010
Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab

NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …

News

Change is needed, concedes NICE chief, but defends record

November 30, 2010
Sales and Marketing Andrew Dillon, NHS reform, NICE, cost-effectiveness, health technology assessment, hta, value-based pricing

The chief executive of NICE acknowledges changes are needed in how drugs are assessed in the UK – including more …

Feature
Novartis’ Afinitor (everolimus)

Novartis fails to sway NICE with Afinitor deal

November 26, 2010
Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus

Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …

News
Tarceva tablet

Roche set to challenge NICE Tarceva decision

November 25, 2010
Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer

NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …

News

NICE recommends Herceptin for gastric cancer, blocks high dose Glivec

November 24, 2010
Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer

NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …

News

Irish cost-effectiveness guidelines published

November 15, 2010
Sales and Marketing Dr Mairin Ryan, Economic Evaluation of Health Technologies, HIQA, Health Information and Quality Authority, IPHA, Ireland, Irish Pharmaceutical Healthcare Association, NICE, hta

The Irish government has published new health technology assessment guidelines to help decision-makers estimate the cost-effectiveness of medical treatments. The …

News
Blog footer

Digital Pharma: Pfizer and Boehringer’s online COPD awareness

November 12, 2010
Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease

Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …

News
Avastin packs

NICE stands firm on Avastin rejection

November 12, 2010
Sales and Marketing NICE, Roche, avastin, bevacizumab, colon cancer, metastatic colorectal cancer, patient access scheme

NICE has refused to recommend Roche’s blockbuster cancer drug Avastin for the treatment of metastatic colorectal cancer in its final …

News

NICE limits access to cancer drugs, study confirms

November 10, 2010
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta

NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …

News

NICE ‘surprised’ at downgrading of its role

November 5, 2010
Sales and Marketing Andrew Dillon, GP prescribing deicisions, NICE, QALY, incremental cost-effectiveness ratio, value-based pricing

NICE received no warning that its health technology assessment role is to be downgraded, the watchdog’s head has admitted. In …

News

Don’t replace NICE with another ‘misguided experiment’

November 5, 2010
Sales and Marketing NHS, NICE, Stockholm Network, medicines access, risk-sharing

Replacing NICE with a similar system would be detrimental to UK healthcare, according to the Stockholm Network, which further warns …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026